Prophylactic intervention in RadL V-induced lymphomagenesis with an anti-IL-4 monoclonal antibody

Sergio Epzsteyn, Ellen S. Vitetta, Eitan Yefenof

Research output: Contribution to journalArticle

Abstract

Intrathymic inoculation of the radiation leukemia virus (RadLV) into C57BL/6 mice induces thymic lymphomas after 4-6 months. During premalignant latency, a population of RadLV-infected prelymphoma (PL) cells (whose survival is dependent on autostimulation with IL-4) persists in the thymus. PL cells explanted from RadLV-inoculated mice can be propagated in cultures containing IL-4, and in vitro growth of PL cells is effectively inhibited by anti-IL-4 antibodies. We subjected RadLV-inoculated mice to prophylactic treatment with anti-IL-4 antibodies and a virus-specific immunotoxin (IT). Administration of IT delayed the onset of lymphoma but was not curative. Anti-IL-4 antibodies had a similar effect when administered at low doses. High doses of anti-IL-4, given 3-5 weeks after virus inoculation, provided complete protection against lymphoma. These results demonstrate the effectiveness of prophylactic intervention during premalignancy by using antagonists that restrain the growth of PL cells.

Original languageEnglish (US)
Pages (from-to)287-291
Number of pages5
JournalJournal of Immunotherapy
Volume20
Issue number4
DOIs
StatePublished - 1997

Fingerprint

Radiation Leukemia Virus
Interleukin-4
Monoclonal Antibodies
Immunotoxins
Lymphoma
Antibodies
Viruses
Growth
Inbred C57BL Mouse
Thymus Gland
Cell Survival
Population

Keywords

  • Anti-IL-4
  • Immunotoxin
  • Prelymphoma
  • Prevention
  • RadLV

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Prophylactic intervention in RadL V-induced lymphomagenesis with an anti-IL-4 monoclonal antibody. / Epzsteyn, Sergio; Vitetta, Ellen S.; Yefenof, Eitan.

In: Journal of Immunotherapy, Vol. 20, No. 4, 1997, p. 287-291.

Research output: Contribution to journalArticle

@article{06a78f4e39b947039c6cda1a2dca239d,
title = "Prophylactic intervention in RadL V-induced lymphomagenesis with an anti-IL-4 monoclonal antibody",
abstract = "Intrathymic inoculation of the radiation leukemia virus (RadLV) into C57BL/6 mice induces thymic lymphomas after 4-6 months. During premalignant latency, a population of RadLV-infected prelymphoma (PL) cells (whose survival is dependent on autostimulation with IL-4) persists in the thymus. PL cells explanted from RadLV-inoculated mice can be propagated in cultures containing IL-4, and in vitro growth of PL cells is effectively inhibited by anti-IL-4 antibodies. We subjected RadLV-inoculated mice to prophylactic treatment with anti-IL-4 antibodies and a virus-specific immunotoxin (IT). Administration of IT delayed the onset of lymphoma but was not curative. Anti-IL-4 antibodies had a similar effect when administered at low doses. High doses of anti-IL-4, given 3-5 weeks after virus inoculation, provided complete protection against lymphoma. These results demonstrate the effectiveness of prophylactic intervention during premalignancy by using antagonists that restrain the growth of PL cells.",
keywords = "Anti-IL-4, Immunotoxin, Prelymphoma, Prevention, RadLV",
author = "Sergio Epzsteyn and Vitetta, {Ellen S.} and Eitan Yefenof",
year = "1997",
doi = "10.1097/00002371-199707000-00005",
language = "English (US)",
volume = "20",
pages = "287--291",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Prophylactic intervention in RadL V-induced lymphomagenesis with an anti-IL-4 monoclonal antibody

AU - Epzsteyn, Sergio

AU - Vitetta, Ellen S.

AU - Yefenof, Eitan

PY - 1997

Y1 - 1997

N2 - Intrathymic inoculation of the radiation leukemia virus (RadLV) into C57BL/6 mice induces thymic lymphomas after 4-6 months. During premalignant latency, a population of RadLV-infected prelymphoma (PL) cells (whose survival is dependent on autostimulation with IL-4) persists in the thymus. PL cells explanted from RadLV-inoculated mice can be propagated in cultures containing IL-4, and in vitro growth of PL cells is effectively inhibited by anti-IL-4 antibodies. We subjected RadLV-inoculated mice to prophylactic treatment with anti-IL-4 antibodies and a virus-specific immunotoxin (IT). Administration of IT delayed the onset of lymphoma but was not curative. Anti-IL-4 antibodies had a similar effect when administered at low doses. High doses of anti-IL-4, given 3-5 weeks after virus inoculation, provided complete protection against lymphoma. These results demonstrate the effectiveness of prophylactic intervention during premalignancy by using antagonists that restrain the growth of PL cells.

AB - Intrathymic inoculation of the radiation leukemia virus (RadLV) into C57BL/6 mice induces thymic lymphomas after 4-6 months. During premalignant latency, a population of RadLV-infected prelymphoma (PL) cells (whose survival is dependent on autostimulation with IL-4) persists in the thymus. PL cells explanted from RadLV-inoculated mice can be propagated in cultures containing IL-4, and in vitro growth of PL cells is effectively inhibited by anti-IL-4 antibodies. We subjected RadLV-inoculated mice to prophylactic treatment with anti-IL-4 antibodies and a virus-specific immunotoxin (IT). Administration of IT delayed the onset of lymphoma but was not curative. Anti-IL-4 antibodies had a similar effect when administered at low doses. High doses of anti-IL-4, given 3-5 weeks after virus inoculation, provided complete protection against lymphoma. These results demonstrate the effectiveness of prophylactic intervention during premalignancy by using antagonists that restrain the growth of PL cells.

KW - Anti-IL-4

KW - Immunotoxin

KW - Prelymphoma

KW - Prevention

KW - RadLV

UR - http://www.scopus.com/inward/record.url?scp=0031284828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031284828&partnerID=8YFLogxK

U2 - 10.1097/00002371-199707000-00005

DO - 10.1097/00002371-199707000-00005

M3 - Article

VL - 20

SP - 287

EP - 291

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 4

ER -